The EU Drugs Strategy provides a political framework and priorities for actions in the field of drug policies for the period 2013-2020. It builds around two policy fields: drug demand reduction and drug supply reduction; and three cross-cutting themes: coordination, international cooperation and information, research, monitoring and evaluation.

The EU Drugs Strategy requests the Commission to initiate an external mid-term assessment by 2016, in view of preparing a second Action Plan for the period 2017-2020.

In the framework of this evaluation and following the Better Regulation Guidelines, the Commission is conducting a broad stakeholder consultation, including an open public consultation, as outlined also in the roadmap of the evaluation. The stakeholder consultation seeks to gather views from individual citizens, non-profit/private organisations, industry and from national/regional/local public administrations on all 5 objectives of the EU Drugs Strategy and corresponding actions of the Action Plan and on the key evaluation criteria: effectiveness, efficiency, relevance, coherence and EU value added. This public consultation will form part of the evidence base for the evaluation of the EU Drugs Strategy and Action Plan and the work ahead.

A Steering Group, made up all relevant Commission services and the European External Action Service (EEAS) chaired by DG HOME, is consulted regularly at all stages of this evaluation and it has approved the consultation strategy for this evaluation, as well as the questionnaire for the public consultation.

Click here fore more information and learn how to submit your contribution.            

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Thumbnail: Wikipedia Commons